Topical vs Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty: A Double-Blind, Randomized Controlled Trial
Fuente
Este artículo es originalmente publicado en:
http://www.ncbi.nlm.nih.gov/pubmed/26703193
http://www.arthroplastyjournal.org/article/S0883-5403(15)00982-1/abstract
De:
North WT1, Mehran N1, Davis JJ1, Silverton CD1, Weir RM1, Laker MW1.
J Arthroplasty. 2015 Nov 10. pii: S0883-5403(15)00982-1. doi: 10.1016/j.arth.2015.11.003. [Epub ahead of print]
Todos los derechos reservados para:
Copyright © 2015 Elsevier Inc. All rights reserved.
Abstract
BACKGROUND:
Tranexamic acid (TXA) reduces perioperative blood loss in total hip arthroplasty (THA).
METHODS:
In our randomized control trial, 139 patients were enrolled and received 2 g of either topical or intravenous (IV) TXA. Preoperative and postoperative protocols were standardized.
CONCLUSIONS:
IV and topical TXA are effective tools to reduce blood loss and transfusion costs in THA, and we recommend the IV form for ease of use.
Resumen
ANTECEDENTES:
El ácido tranexámico (TXA) reduce la pérdida de sangre perioperatoria en artroplastia total de cadera (THA).
MÉTODOS:
En nuestro ensayo controlado aleatorizado, 139 pacientes se inscribieron y recibieron 2 g de TXA ya sea tópica o por vía intravenosa (IV). Protocolos Preoperatorios y postoperatorios fueron estandarizados.
CONCLUSIONES:
Vía intravenosa IV y TXA tópica son herramientas eficaces para reducir la pérdida de sangre y los costos de transfusión en THA, y recomendamos la forma IV para facilitar su uso.
Copyright © 2015 Elsevier Inc. All rights reserved.
KEYWORDS:
cost reduction in primary hip arthroplasty; perioperative blood conservation; risk reduction in primary hip arthroplasty; total hip arthroplasty; tranexamic acid
- PMID:26703193 [PubMed – as supplied by Publisher]
Ortopedia y Traumatología / Mis huesos y ArticulacionesCirugía Articular y Artroscopia